FibroGen Inc. (FGEN)

43.00
2.32 5.70
NASDAQ : Health Technology
Prev Close 40.68
Open 40.70
Day Low/High 40.65 / 43.29
52 Wk Low/High 33.51 / 68.55
Volume 1.05M
Avg Volume 837.20K
Exchange NASDAQ
Shares Outstanding 86.15M
Market Cap 3.50B
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CTB, FII, GVA, MIME, PETX Downgrades: DF, FGEN, MUX, NXGN, PANL, TAIT Initiations: DESP Read on to get TheStreet Quant Ratings' detailed report:

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: EOG, FGEN, GASS, GHC, SATS Downgrades: ALB, CFBK, CLI, DISCB, FORM, HCCI, IONS, KOP, LTC, MNRO, PNTR, SRE Initiations: FRAC, JELD, REVG Read on to get TheStreet Quant Ratings' detailed report:

FibroGen To Report Fourth Quarter And Full Year 2017 Financial Results On Tuesday, February 27, 2018

FibroGen To Report Fourth Quarter And Full Year 2017 Financial Results On Tuesday, February 27, 2018

Conference Call and Audio Webcast Scheduled for 5:00 p.m. ET (2:00 p.m. PT)

Jobs Plus Earnings Equal Buys: Cramer's 'Mad Money' Recap (Friday 11/3/17)

Jobs Plus Earnings Equal Buys: Cramer's 'Mad Money' Recap (Friday 11/3/17)

Will the benign backdrop continue next week? Cramer has a defensive game plan, in case earnings chill the market.

FibroGen To Report Third Quarter Financial Results On Wednesday, November 8, 2017

FibroGen To Report Third Quarter Financial Results On Wednesday, November 8, 2017

Conference Call and Webcast Scheduled for 5:00 p.m. ET (2:00 p.m. PT)

Get Ready for an Earnings Onslaught: Cramer's 'Mad Money' Recap (Friday 10/20/17)

Get Ready for an Earnings Onslaught: Cramer's 'Mad Money' Recap (Friday 10/20/17)

Jim Cramer's game plan is jam-packed for next week; this is the heart of earnings season.

Magellan Midstream, Walt Disney, Align Technology: 'Mad Money' Lightning Round

Magellan Midstream, Walt Disney, Align Technology: 'Mad Money' Lightning Round

Jim Cramer is bullish on Magellan Midstream, Walt Disney, Align Technology and Schlumberger.

Spectrum Shares Surge on Data for Lung Cancer Drug -- Biotech Movers

Spectrum Shares Surge on Data for Lung Cancer Drug -- Biotech Movers

The Henderson, Nev.-based company said interim data from a Phase 2 study showed an objective response rate of 73%.

Kratos Defense, Fibrogen, Nike: 'Mad Money' Lightning Round

Kratos Defense, Fibrogen, Nike: 'Mad Money' Lightning Round

A roundup of stocks Mad Money viewers asked Jim Cramer about Tuesday.

Activists Can Boost Shares: Cramer's 'Mad Money' Recap (Tuesday 10/10/17)

Activists Can Boost Shares: Cramer's 'Mad Money' Recap (Tuesday 10/10/17)

Activist investors have helped smaller shareholders win higher valuations for their holdings.

The Flippers Are at Work and the Bears Are Hopeful

The Flippers Are at Work and the Bears Are Hopeful

Apple and its suppliers are dragging the market down.

Shark Bites: Jupai Holdings Looks Good on a Dull Day

Shark Bites: Jupai Holdings Looks Good on a Dull Day

Why I like this China-based wealth management firm.

Mid-afternoon Musings; Amazon Shorting: Doug Kass' Views

Mid-afternoon Musings; Amazon Shorting: Doug Kass' Views

Doug Kass shares his thoughts on some stocks and also discusses his thinking on Amazon.

Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment

Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment

A number of biotech-related stocks were down pre-market after announcing plans for public offerings.

Seeing Better Action in Individual Stocks

Seeing Better Action in Individual Stocks

But the indices are in a trading range and it really boils down to finding the right vehicles to ride.

Back to Basics in Biotech

Back to Basics in Biotech

Stop losses do not work in this part of the market.

Back to Basics in Biotech

Back to Basics in Biotech

Stop losses do not work in this part of the market.

Biotech Movers: FibroGen Leaps on Results for Pulmonary Fibrosis Study

Biotech Movers: FibroGen Leaps on Results for Pulmonary Fibrosis Study

FibroGen, Depomed and Valeant were among the biotech stock movers in premarket trading on Aug. 8.

TheStreet Quant Rating: D+ (Sell)